CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

PRO-SERO-COVWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2225 SensiumVitals wearable sensor Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic - PRO-SERO-COV

The question of the immune response of the population, particularly of professional populations in contact with vulnerable populations (such as those with chronic conditions such as cancer), is an important issue. Knowing the evolution of this response over time in this population can help answer outstanding questions. The PRO-SERO-COV study is a seroprevalence study of caregivers working in the hospital sector with a follow-up at 3 months and 12 months. The objective is to evaluate and monitor at 3 and 12 months the serological immune status to an infection by the SARS-CoV-2 virus in active volunteer professionals working at the Institut Bergonié with different types of exposure: healthcare professionals and professionals in other services.

NCT04426006 Sars-CoV2 Serum; Disease Other: PRO-SERO-COV

Primary Outcomes

Description: This will be determined from the detection of specific antibodies (immunoglobulins: IgM and IgG) or total antibodies carried out using the ELISA/ECLIA method allowing qualitative and semi-quantitative measures. These ELISA/ECLIA tests will be carried out in the medical biology laboratory of the Institut Bergonié.

Measure: Serological immune status to an infection by the SARS-CoV-2 virus

Time: Time 0 (Inclusion)

Secondary Outcomes

Description: This will be determined from the detection of specific antibodies (immunoglobulins: IgM and IgG) or total antibodies carried out using the ELISA/ECLIA method allowing qualitative and semi-quantitative measures. These ELISA/ECLIA tests will be carried out in the medical biology laboratory of the Institut Bergonié.

Measure: Serological immune status to an infection by the SARS-CoV-2 virus

Time: 3 months, 12 months

Description: This will be determined from the detection of specific antibodies (immunoglobulins: IgA) carried out using the ELISA/ECLIA method allowing qualitative and semi-quantitative measures. These ELISA/ECLIA tests will be carried out in the medical biology laboratory of the Institut Bergonié.

Measure: Serological immune status to an infection by the SARS-CoV-2 virus

Time: Time 0 (inclusion), 3 months, 12 months

Description: Assessment using a " rapid test on cassette ".

Measure: The serological immune status to infection with the SARS-CoV-2 virus will also be determined from the different antibody isotypes (IgG and IgM), from a rapid diagnostic unit test (RDT).

Time: Time 0 (inclusion), 3 months, 12 months

Measure: kinetics of antibody production (IgG) against the SARS-CoV-2 virus

Time: Time 0 (inclusion), 3 months, 12 months

Measure: kinetics of antibody production (IgM) against the SARS-CoV-2 virus

Time: Time 0 (inclusion), 3 months, 12 months

Measure: kinetics of antibody production (IgA) against the SARS-CoV-2 virus

Time: Time 0 (inclusion), 3 months, 12 months

Description: Defined by a positive result for the molecular test for the detection of the SARS-CoV-2 coronavirus genome by RT-PCR.

Measure: active COVID-19 infection

Time: Time 0 (inclusion), 3 months, 12 months

Description: GAD-7 self-questionnaire (Spitzer et al. 2006), whose score varies from 0 to 21. The recommended threshold for estimating generalized anxiety is 10 points

Measure: symptoms of anxiety

Time: Time 0 (inclusion), 3 months, 12 months

No related HPO nodes (Using clinical trials)